Filing Flows › Anika Therapeutics (ANIK) › R&D spending
Anika Therapeutics (ANIK) R&D spending by quarter
Anika Therapeutics' R&D spending was $7.9M in Q3 2026 (third quarter 2026), +8% from Q2 2026. Over the last 7 quarters it ranged from $6.1M (Q1 2025) to $7.9M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $7.9M | +8% | +14% |
| Q2 2026 | $7.3M | +9% | +16% |
| Q1 2026 | $6.7M | +4% | +11% |
| Q4 2025 | $6.5M | -7% | — |
| Q3 2025 | $6.9M | +10% | — |
| Q2 2025 | $6.3M | +4% | — |
| Q1 2025 | $6.1M | — | — |
Q3 2026 at a glance
Anika Therapeutics, Q3 2026: revenue $30.6M (+10% year over year), operating margin -2.3%, net loss $311K, operating cash flow $8.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Anika Therapeutics' R&D spending?
Anika Therapeutics' R&D spending was $7.9M in Q3 2026 (third quarter 2026), +8% from Q2 2026.
How has Anika Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $6.1M (Q1 2025) to $7.9M (Q3 2026).